Latest news and updates

Rosalind Study

Cure51’s flagship study compares long-term survivors with matched controls to uncover new drug targets.

france-oncology-centers-cancer-research
Happy 14 Juillet! French oncology centers are an important part of our oncology network

Liberté, Égalité, Fraternité… and a shared commitment to advance cancer research

exceptional-survivors-blueprint-defeat-cancer
Why do exceptional survivors hold the blueprint to defeating cancer?

Why do exceptional survivors hold the blueprint to defeating cancer?

world-largest-clinical-oncology-network
New strategic partnerships: our global oncology network continues to expand!

New strategic partnerships: our global oncology network continues to expand!

Emna-Makhlouf-Agathe-Lecaron-Ex-Vitro
Emna Makhlouf, Chief of Staff: "Working with cancer survivors gives a lot of purpose to what we do"

Emna Makhlouf, Chief of Staff: "Working with cancer survivors gives a lot of purpose to what we do"

cure51-servier-paris-saclay-pscc-annual-event
Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

GBM-ES-SCLC- mPDAC-cancer
The Rosalind Study | Decoding Exceptional Cancer Survival Across GBM, ES-SCLC and mPDAC

The Rosalind Study | Three cohorts, one mission: decoding exceptional Cancer survival across GBM, ES-SCLC and mPDAC

Global-Cancer-Research-Compliance
How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

pancreatic-cancer-patient-advocacy
Advancing Cancer Research Through Patient Advocacy

Working hand in hand with patient advocates to advance Pancreatic Cancer Research

A Strategic Partnership to Rethink Pancreatic Cancer Treatment: Cure51 × CRCM × Institut Paoli-Calmettes

A Strategic Partnership to Rethink Pancreatic Cancer Treatment: Cure51 × CRCM × Institut Paoli-Calmettes

simon-istolainen-nicolas-wolikow-cure51
Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

Rosalind-Study-worldwide-oncology-network
Celebrating a huge Rosalind Study milestone: 115+ worldwide partner oncology centers!

Rosalind Study Milestone: 115+ Centers Join Cure51’s International Oncology Network

nicolas-wolikow-cure51-cancer-research
Cure51's CEO Nicolas Wolikow: "Reverse-Engineering the Cure to Cancer: A New Paradigm in Oncology Research"

Cure51's CEO Nicolas Wolikow: "Reverse-Engineering the Cure to Cancer: A New Paradigm in Oncology Research"

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Follow us

Linkedin

Facebook

Instagram

Contact us

Contact us

Follow us

Linkedin

Facebook

Instagram

Contact us

ROSALIND

Contact us